From Synovial Tissue to Peripheral Blood: Myeloid Related Protein 8/14 Is a Sensitive Biomarker for Effective Treatment in Early Drug Development in Patients with Rheumatoid Arthritis

• Ivy Y. Choi,

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands

  ⨯
• Danielle M. Gerlag,

  Current address: GlaxoSmithKline Research & Development, Cambridge, United Kingdom

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands

  ⨯
• Dirk Holzinger,

  Affiliations Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Muenster, Muenster, Germany, Institute of Immunology, University Hospital Muenster, Muenster, Germany

  ⨯
• Johannes Roth,

  Affiliation Institute of Immunology, University Hospital Muenster, Muenster, Germany

  ⨯
• Paul P. Tak

  * E-mail: paul-peter.x.tak@gsk.com

  Current address: University of Cambridge, Cambridge, United Kingdom; GlaxoSmithKline Research & Development, Stevenage, United Kingdom

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands

  ⨯